The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase I study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines the rationale for a Phase I study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis (MF), explaining that pre-clinical data has shown synergistic activity between the CDK4/6 inhibitor abemaciclib and ruxolitinib. This combination may represent a promising option in patients who are resistant to ruxolitinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
